Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
UniCAR-NK
- Development stage
- Preclinical
- Lead developer
- AvenCell Therapeutics
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
UniCAR-NK is an allogeneic **CAR-NK cell therapy** based on genetically engineered NK-92 cells that express the modular UniCAR receptor platform developed at Helmholtz-Zentrum Dresden-Rossendorf and advanced by GEMoaB. The receptor uses an extracellular single-chain variable fragment directed against the peptide epitope E5B9 together with CD28 transmembrane and costimulatory elements and a CD3 zeta signaling domain. UniCAR-NK cells do not directly bind tumor antigens; instead, they are activated and redirected by separate tumor-specific target modules that bridge the UniCAR receptor to cancer antigens such as GD2 or HER2. This modular on off switch design is intended to improve safety, controllability, and retargeting flexibility across solid tumors and hematologic malignancies, and the program has been described primarily in preclinical development.
- Other names
- UniCAR NK cellsUniCAR-engineered NK-92 cellsUniCAR-modified NK-92 cells
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)GD2
Beyond the preview
Go deeper on UniCAR-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on UniCAR-NK.